Component Therapy (CT)
Phase 3Biologic
Component Therapy (CT) is one of 39 biologic programs targeting Hemorrhage. It is currently in Phase 3.
2
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
137 competitors in Hemorrhage
#DrugCompanyPhaseTrials
1Cytotec
PfizerPhase 3
Cyklokapron
AAmring
Phase 3
Activase
RochePhase 3
Glypressin
MMallinckrodt
Phase 3
Indocin
LLife Extension Foundation Inc.
Phase 3
Betadine
BBecton, Dickinson and Company
Phase 3
Zocor
OOrganon and Co
Phase 3
Statins
SanofiPhase 3
Epoetin Beta
RochePhase 3
Platelets
LLeiden University Medical Center
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Component Therapy (CT). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- PPhilip Spinella